Department of Biotechnology

Department of Biotechnology has been granted 26 US utility patents between 2015 and 2024, placing Department of Biotechnology at rank #11,626 across all assignees tracked by PlainPatent. This portfolio spans 25 distinct Cooperative Patent Classification (CPC) subclasses, averaging 10.7 claims per patent with primary concentration in C12P (FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE). As a Foreign Corporation, Department of Biotechnology is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 39.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 16 grants, compared with 10 in the 2015–2019 window — a +60% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Department of Biotechnology's 10.7 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while a multi-domain presence across 25 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Department of Biotechnology against peers pursuing similar technology classes.